Two new papers from/in collaboration with our group

Paper 1:

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors

Pierre Dillard, Nicholas Casey, Sylvie Pollmann, Patrik Vernhoff, Gustav Gaudernack, Gunnar Kvalheim, Sébastien Wälchli & Else Marit Inderberg

Paper 2:

Circulating Tumor Cell Persistence Associates with Long-TermClinical Outcome to a Therapeutic Cancer Vaccine inProstate Cancer

Ingrid Jenny Guldvik, Lina Ekseth, Amar U. Kishan, Andreas Stensvold, Else Marit Inderberg and Wolfgang Lilleby

Abstracts:

Scroll to top

Recent publications

Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, Benard E, Kaveh F, Caulier B, Helgestad Gjerde C, García de Jalón E, Warren DJ, Lindemann K, Rokkones E, Davidson B, Myhre MR, Kvalheim G, Bjørge L, McCormack E, Inderberg EM, Wälchli S (2024)
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16
J Immunother Cancer, 12 (4)
DOI 10.1136/jitc-2023-008179, PubMed 38604812

Maggadottir SM, Dueland S, Mensali N, Hamre H, Andresen PA, Myhre MR, Juul HV, Bigalke I, Lundby M, Hønnåshagen TK, Sæbøe-Larssen S, Josefsen D, Hagtvedt T, Wälchli S, Kvalheim G, Inderberg EM (2024)
Transient TCR-based T-cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer
Mol Ther (in press)
DOI 10.1016/j.ymthe.2024.04.009, PubMed 38582964

Klee CH, Villatoro A, Casey NP, Inderberg EM, Wälchli S (2023)
In vitro re-challenge of CAR T cells
Methods Cell Biol, 183, 335-353
DOI 10.1016/bs.mcb.2023.06.003, PubMed 38548418

More publications